Outpatient consultations
Secretaries
- Opening hours: Monday to Friday, 8am to 6.30pm
- Telephone: +33(0)2 31 24 34 48
- Location: at the proton therapy centre on the CYCLHAD site in Caen
The team
- Head of department:
Pathologies / Spécialités
- Radiothérapie
- Protonthérapie
Fonctions exercées au CFB
- Oncologue radiothérapeute
- Chef de service de Radiothérapie
- Coordinateur scientifique d’ARCHADE
Domaines d’expertise
- Hadronthérapie,
- Cancérologie digestive,
- Radiobiologie clinique
Enseigne
Au Centre François Baclesse :
- Enseignement du Diplôme d’Etudes Spécialisées (DES) de radiothérapie
Au niveau régional et national :
- Cours sur la radiothérapie pour l’Université de Caen
- Cours aux Masters 2 de Radioprotection et M2 de Physique médicale à l’Université de Grenoble
Membre de…
Au Centre François Baclesse :
- l’UCP Digestive
- le staff de Protonthérapie
Au niveau national :
- la SFRO (société française de radiothérapie oncologique)
Au niveau international :
- du réseau ENLIGHT (European Network for Light Ion Therapy)
- l’European Particle Therapy Network (NPTN)
- Supervisor: Magali Micaud
- Radiation oncologists:
- Pr Jacques Balosso
- Dr Mathieu Cesaire
- Dr Charlotte Demoor-Goldschmidt
- Dr Julien Geffrelot
- Pr Jean-Louis Habrand
- Dr Delphine Lerouge
- Dr Paul Lesueur
- Dr Fernand Missohou
- Dr Dinu Stefan
- Prof. Juliette Thariat
Department mission
Since August 2018, patients are treated by proton therapy in Caen, via the Centre François Baclesse radiotherapy department, on the Cyclhad – Normandy Proton Therapy Centre site.
Treatment by proton therapy proposed by the Centre François Baclesse is a national healthcare offer. This is the third site in France to propose this therapeutic modality, after the sites in Orsay (Ile-de-France) and Nice. Given the rarity of this type of equipment throughout France, the Centre François Baclesse proposes this therapeutic option in coordination with other centres, for patients from across France.
Conventional radiotherapy uses photon beams (X-rays). Proton therapy uses proton beams. The difference between proton therapy and conventional radiotherapy lies in the manner in which the energy from the employed beam is delivered. In the case of proton beams, the dose can be delivered to the tumour without irradiating beyond this zone.
Healthcare offer and expertise
Adult cancers
For adults, proton therapy is currently indicated in tumours for which balistic and radiological constraints are important. A few indications are currently validated via consensus by the French health authorities.
Treated cancers:
- Malignant cartilage tumours: chondrosarcomas, chordomas
- ENT tumours
- Tumours close to the spine, chest or abdominal tumours, of low mobility
- Tumours of the eye or orbit
- Curative re-irradiation
- Non aggressive brain tumours (meningiomas, paragangliomas – also referred to as chemodectomas, neurinomas also referred to as scwhannomas, craniopharyngiomas), etc.
Paediatric cancers
Thanks to its balistic qualities, proton therapy exposes children to a far more reliable dose around the tumour than standard radiotherapy using photons. Its main benefits are reduced local toxicity, both acute and delayed, and reduced functional sequelae (auditive, endocrinian, cognitive), together with a lower very long-term carcinogenic risk.
Treated cancers:
- Brain tumours:
- Medulloblastomas and other PNETs (Primitive Neuro Ectodermic Tumours)
- Gliomas
- Ependymomas
- Tumour at the base of the skull: Craniopharyngioma
- Soft tissue tumours: rhabdomyosarcomas (RMS), mesenchymal sarcomas
- Tumours of the nervous system: neuroblastomas
- Other paediatric tumours
The department’s equipment and facilities
On the Cyclhad site:
- Access to 1 proton therapy machine: Proteus One® – IBA SA (2018)
The Centre François Baclesse uses Proteus One (IBA) proton therapy equipment, which includes a mobile treatment system (gantry) with pencil beam scanning (PBS), enabling conformational treatment with 3D-modulation of delivered dose.
Results
Activity data 2019
- Number of external radiotherapy sessions: 2,373